Drug intelligence / Profile preview

LX12002

Development stage: Preclinical
Lead developer: Loxagen
Modality: Small Molecules

Overview

LX12002 is a preclinical-stage small molecule inhibitor of arachidonate 12-lipoxygenase (ALOX12, also known as 12LOX) being developed by Loxagen. The drug is designed to treat heparin-induced thrombocytopenia (HIT) by selectively inhibiting ALOX12, which is intended to reduce thrombosis without increasing the risk of bleeding. LX12002 is currently in the lead optimization stage of preclinical development.

Beyond the preview

Go deeper on LX12002.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on LX12002.

Explore the full profile